Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion

SYNCAR-001 + STK-009 combination will be studied in two distinct lupus patient populations: non-renal systemic lupus erythematosus (SLE) and lupus nephritis (LN) MENLO PARK, Calif. -- Synthekine Inc., an engineered [...]